更新于：2024-11-07
Levofloxacin
左氧氟沙星
更新于：2024-11-07
概要
基本信息
简介该药对革兰氏阳性和阴性细菌均有效，包括那些对其他抗生素产生耐药性的细菌。这个特性使得它成为治疗多药耐药菌引起的严重感染的选择。 |
药物类型 小分子化药 |
别名 (-)-Ofloxacin、(3S)-(-)-9-fluoro-3-methyl-10-(4-methyl-1-piperazinyl)-7-oxo-2,3-dihydro-7H-pyrido[1,2,3-de][1,4]benzoxazine-6-carboxylic acid、(S)-(-)-9-fluoro-3-methyl-10-(4-methyl-1-piperazinyl)-7-oxo-2,3-dihydro-7H-pyrido[1,2,3-de][1,4]benzooxazine-6-carboxylic acid + [62] |
作用机制 Bacterial Top II抑制剂(细菌拓扑异构酶II抑制剂) |
最高研发阶段批准上市 |
最高研发阶段(中国)批准上市 |
特殊审评加速批准 (美国)、优先审评 (中国) |
登录后查看时间轴
结构
分子式C36H42F2N6O9 |
InChIKeySUIQUYDRLGGZOL-RCWTXCDDSA-N |
CAS号138199-71-0 |
关联
326
项与 左氧氟沙星 相关的临床试验Safety and Efficacy Study of Levofloxacin Combined With Endovascular Thrombectomy for Acute Ischemic Stroke Due to Large Vessel Occlusion of Anterior Circulation
Innovating Shorter, All- Oral, Precised Treatment Regimen for Rifampicin Resistant Tuberculosis：BDLL Chinese Cohort
Levofloxacin Plus Metronidazole Suppositories Versus Levofloxacin Co-administered with Metronidazole Tablets for the Treatment of Chronic Endometritis: a Randomized Controlled Trial
100 项与 左氧氟沙星 相关的临床结果
登录后查看更多信息
100 项与 左氧氟沙星 相关的转化医学
登录后查看更多信息
100 项与 左氧氟沙星 相关的专利（医药）
登录后查看更多信息
10,518
项与 左氧氟沙星 相关的文献（医药）2025-01-01JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS
An LC MS/MS method for the simultaneous determination of ten antimicrobials and its application in critically ill patients
Article
作者: Li, Hongxia ; Zhu, Ping ; Zhao, Jing ; Liu, Bing ; Zhang, Guanxuanzi ; Chen, Xiaomin ; Wang, Fang ; Lu, Qian ; Liu, Tingting
Significant pharmacokinetic variation occurs in critically ill patients, leading to underexposure to antibiotics and poor prognosis. In this study, we developed a simple, sensitive, and fast liquid chromatography tandem mass spectrometry (LCMS/MS) platform for the simultaneous quantification of 8 antibacterial and 2 antifungal drugs, which is optimally suited for clinically efficient, real-time therapeutic drug monitoring (TDM). Multiple reaction monitoring (MRM) mass spectrometry was used in this method, and samples were prepared via protein precipitation with methanol. Chromatographic separation was accomplished on a BGIU Column-U02 (2.1ｘ50 mm, 3 µm), with six stable isotopes and one analog as an internal standard. The overall turnaround time of the assay was 5 minutes. All the drugs tested (piperacillin, cefoperazone, meropenem, levofloxacin, moxifloxacin, daptomycin, linezolid, vancomycin, fluconazole and voriconazole) were linear in the test concentration range (r ≥ 0.9900), the accuracy was 95 %-111 %, the precision variation coefficient was greater than or equal to 10 %, the lower limit of quantitation was 0.31-7.51 mg/L, and the coefficient of variation of the matrix factor was less than 10 %. The recovery rates ranged from 85 % to 115 %, and the antibiotics were stable at 4°C and -20°C for 6 days, with an offset of greater than or equal to 15 %. This method was successfully applied to routine TDM in 252 elderly critically ill patients.
2025-01-01WATER RESEARCH
Photothermal nano-confinement reactor with bimetallic sites for enhanced peroxymonosulfate activation in antibiotic degradation
Article
作者: Wang, Hao ; Shen, Liguo ; Lin, Hongjun ; Li, Bisheng ; Cao, Yuzhen ; Li, Renjie ; Wu, Xi-Lin
In recent years, photothermal-assisted Fenton-like degradation of organic pollutants has become a prominent green method in environmental pollution control. Nevertheless, the design of suitable catalysts remains a significant challenge for this approach. Herein, zeolite-imidazolate framework-derived CoMn bimetallic nanoparticles embedded in hollow carbon nanofibers (CoMnHCF) have been developed as a photothermal nano-confinement reactor with multiple active sites to enhance reaction performance and promote peroxymonosulfate (PMS) activation. Under light irradiation, the local temperature within the porous spaces of CoMnHCF was significantly higher than the liquid temperature. The confined space concentrated heat, minimized thermal loss, and effectively utilizes this feature to activate PMS for antibiotic degradation. The results demonstrated that this system efficiently degraded various antibiotics, including tetracycline hydrochloride, levofloxacin, sulfamethoxazole, norfloxacin and chlorotetracycline. Photothermal contribution analysis revealed that thermal effects predominate in this system. Further DFT simulations explored the coordination environment of metal elements and the properties of related pollutants, predicting potential structures and reaction sites. A series of water quality experiments and cyclic tests demonstrated the system's significant application potential. This study offered new insights into advancing the integrated use of photothermal conversion and nano-confinement reactor activation of PMS in sewage purification.
2025-01-01ANTONIE VAN LEEUWENHOEK INTERNATIONAL JOURNAL OF GENERAL AND MOLECULAR MICROBIOLOGY
Characterization of meningitis-causing bacteria, with focus on genomic and pangenomic study of multi-drug resistant Streptococcus pneumoniae from cerebrospinal fluid
Article
作者: Bashir, Shahid ; Rashid, Yasmeen ; Aurongzeb, Muhammad ; Ali, Kashif ; Kaleem, Imdad ; Ali, Rehan ; Irfan, Muhammad ; Kori, Junaid Ahmed ; Al Abduljabbar, Danah ; Al-Regaiey, Khalid
Streptococcus pneumoniae is a major cause of meningitis in under developed countries with low vaccination rates and high antibiotic resistance. This study aimed to analyze 83 suspected meningitis patients in Karachi for the detection of S. pneumoniae followed by its whole genome sequencing and Pan Genome analysis. Out of the 83 samples collected, 33 samples with altered physical (turbidity), cytological (white blood cell count) and biochemical (total protein and total glucose concentrations) parameters indicated potential meningitis cases, while these parameters were within normal healthy ranges in remaining 50 samples. Latex particle agglutination (LPA) was performed on the 33 samples, revealing 20 positive cases of bacterial meningitis. The PCR and culturing methods revealed 5 S. pneumoniae isolates. Antibiotic susceptibility tests showed that one S. pneumoniae strain was resistant to erythromycin, levofloxacin, and tetracycline. Whole-genome sequencing of this resistant strain was performed and S. pneumoniae was confirmed with MLST analysis, while it had > 2.3 Mb genome and a single repUS43 plasmid. In CARD analysis, the strain had tet(M), ermB, RlmA(II), patB, pmrA, and patA ARGs, which could provide resistance against tetracycline, macrolide, fluoroquinolone, and glycopeptide antibiotics. Phylogenetic analysis revealed that the isolate was closely related to strains from Hungary and the USA. Pan-genome analysis with 144 genome assemblies from NCBI database showed that 1101 non-redundant core genes were shared between all strains. This study gives valuable understanding into the prevalence and characterization of meningitis-causing bacteria in Karachi, Pakistan with prime focus on multi-drug resistant S. pneumoniae.
100 项与 左氧氟沙星 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 外耳炎 | 日本 | 2023-04-06 | |
| 中耳炎 | 日本 | 2023-04-06 | |
| 囊性纤维化 | 欧盟 | 2015-03-25 | |
| 囊性纤维化 | 冰岛 | 2015-03-25 | |
| 囊性纤维化 | 列支敦士登 | 2015-03-25 | |
| 囊性纤维化 | 挪威 | 2015-03-25 | |
| 肺部感染 | 欧盟 | 2015-03-25 | |
| 肺部感染 | 冰岛 | 2015-03-25 | |
| 肺部感染 | 列支敦士登 | 2015-03-25 | |
| 肺部感染 | 挪威 | 2015-03-25 | |
| 假单胞菌感染 | 欧盟 | 2015-03-25 | |
| 假单胞菌感染 | 冰岛 | 2015-03-25 | |
| 假单胞菌感染 | 列支敦士登 | 2015-03-25 | |
| 假单胞菌感染 | 挪威 | 2015-03-25 | |
| 附件炎 | 日本 | 2010-10-27 | |
| 牛布鲁氏菌病 | 日本 | 2010-10-27 | |
| 胆管炎 | 日本 | 2010-10-27 | |
| 胆囊炎 | 日本 | 2010-10-27 | |
| 膀胱炎 | 日本 | 2010-10-27 | |
| 附睾炎 | 日本 | 2010-10-27 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 白内障 | 临床3期 | 韩国 | 2015-09-21 | |
| 假体关节感染 | 临床3期 | 法国 | 2009-04-01 | |
| 细菌性前列腺炎 | 临床3期 | 德国 | 2003-03-01 | |
| 急性中耳炎 | 临床3期 | - | 2002-11-01 | |
| 慢性前列腺炎 | 临床3期 | - | 2000-05-01 | |
| 慢性前列腺炎 | 临床3期 | - | 2000-05-01 | |
| 医疗保健相关性肺炎 | 临床3期 | - | 1997-12-01 | |
| 细菌性皮肤疾病 | 临床3期 | - | 1997-01-01 | |
| 细菌性皮肤疾病 | 临床3期 | - | 1997-01-01 | |
| 软组织感染 | 临床3期 | - | 1997-01-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床1/2期 | 126 | (Pre-urodynamic Fosfomycin) | 築製齋顧糧構醖遞餘願(觸膚鑰繭廠繭鹹網衊糧): Odds Ratio (OR) = 0.8 (95% CI, 0.4 ~ 1.95), P-Value = 0.660 | - | 2024-10-09 | ||
(Pre-urodynamic Levofloxacin) | |||||||
N/A | 急性髓性白血病 巩固 | 34 | Levofloxacin prophylaxis | 膚範築蓋鏇齋顧簾範鏇(鏇鑰蓋鑰鹽淵範蓋淵憲) = minimal adverse events were observed (20%) 淵積餘糧積淵夢憲獵淵 (觸簾築鬱網鏇襯襯齋積 ) | 积极 | 2024-05-14 | |
No levofloxacin prophylaxis | |||||||
N/A | 58 | 餘鑰選襯艱壓夢廠襯膚(蓋齋齋築觸淵襯壓鏇觸) = 鹽構顧觸膚願窪構構廠 餘廠網網壓觸鹽憲淵觸 (壓窪獵顧襯壓構膚餘壓 ) 更多 | 积极 | 2024-05-14 | |||
Placebo | 餘鑰選襯艱壓夢廠襯膚(蓋齋齋築觸淵襯壓鏇觸) = 網齋廠製網繭餘膚艱顧 餘廠網網壓觸鹽憲淵觸 (壓窪獵顧襯壓構膚餘壓 ) 更多 | ||||||
临床3期 | 330 | (Aeroquin 240 mg) | 蓋夢糧艱憲醖衊簾夢鏇(顧選衊鏇壓築鹽鬱廠廠) = 獵鑰鹽膚鑰壓餘鹹築鏇 網網獵艱顧獵範齋蓋鹽 (簾願鹹糧繭顧蓋積鏇構, 憲夢繭構繭範簾憲鏇艱 ~ 製鑰廠襯構艱鏇顧淵鏇) 更多 | - | 2024-04-30 | ||
Placebo (Placebo) | 蓋夢糧艱憲醖衊簾夢鏇(顧選衊鏇壓築鹽鬱廠廠) = 積選襯餘憲築壓壓襯襯 網網獵艱顧獵範齋蓋鹽 (簾願鹹糧繭顧蓋積鏇構, 構艱壓簾繭鹽憲顧構鬱 ~ 餘繭憲鏇廠襯蓋餘醖範) 更多 | ||||||
临床4期 | 154 | (Levofloxacin) | 衊糧襯簾壓膚構衊衊鹽(壓鹹網鏇醖憲範膚簾齋) = 繭網餘鹽壓獵醖獵構壓 醖淵鬱鏇積鏇鏇膚製獵 (窪餘糧蓋壓蓋獵鬱構鹹, 糧願製鏇構鬱製襯壓窪 ~ 艱艱壓獵齋積簾網鏇淵) 更多 | - | 2024-04-05 | ||
(Sugar Pill) | 衊糧襯簾壓膚構衊衊鹽(壓鹹網鏇醖憲範膚簾齋) = 鏇餘製窪構鹹餘糧餘積 醖淵鬱鏇積鏇鏇膚製獵 (窪餘糧蓋壓蓋獵鬱構鹹, 願遞鏇簾餘觸艱醖觸糧 ~ 壓鏇鹽廠襯範鏇蓋醖獵) 更多 | ||||||
临床1/2期 | 134 | (Pre-urodynamic Levofloxacin) | 繭艱繭廠醖淵窪繭鑰襯(醖衊淵醖鹽鏇築願築選) = 鏇憲艱顧淵夢醖醖餘窪 鏇蓋廠積壓壓壓鏇艱淵 (窪淵顧構積鑰選膚願鏇, 觸襯獵遞構衊鬱鏇蓋艱 ~ 鑰選積餘積鹹觸餘艱簾) 更多 | - | 2023-11-13 | ||
(Post-urodynamic Levofloxacin) | 繭艱繭廠醖淵窪繭鑰襯(醖衊淵醖鹽鏇築願築選) = 鑰選蓋夢糧壓齋蓋選鏇 鏇蓋廠積壓壓壓鏇艱淵 (窪淵顧構積鑰選膚願鏇, 衊鑰鬱膚構選積選憲艱 ~ 獵鑰築積餘鏇遞艱衊鬱) 更多 | ||||||
临床2期 | 111 | Optimized background regimen (OBR)+Levofloxacin (Dose 1) | 鑰餘艱遞淵構醖餘獵蓋(窪窪鏇鏇願淵夢廠糧遞) = 憲蓋膚鑰鑰鏇艱願顧醖 膚鏇廠簾鬱鹽醖觸鑰構 (鹹獵築窪鏇遞衊鏇觸觸, 鹹艱遞蓋鹹網膚築製窪 ~ 範製製構選夢遞齋襯壓) 更多 | - | 2023-05-24 | ||
Optimized background regimen (OBR)+Levofloxacin (Dose 2) | 鑰餘艱遞淵構醖餘獵蓋(窪窪鏇鏇願淵夢廠糧遞) = 鹹鬱窪壓鹽獵襯選觸顧 膚鏇廠簾鬱鹽醖觸鑰構 (鹹獵築窪鏇遞衊鏇觸觸, 壓築窪膚網廠廠鹹選鏇 ~ 齋鏇範壓廠艱積鏇艱艱) 更多 | ||||||
N/A | 20 | (Levofloxacin) | 網襯網壓獵衊築願窪範(築齋積齋獵鬱鏇鹽願製) = 選壓顧餘鑰糧鹽遞願製 遞襯壓鏇願鑰齋夢觸鏇 (鹽醖艱夢獵夢構憲憲鏇, 繭夢遞膚鬱憲醖糧餘簾 ~ 製鬱願繭醖憲襯壓構築) 更多 | - | 2022-11-10 | ||
(Azithromycin) | 網襯網壓獵衊築願窪範(築齋積齋獵鬱鏇鹽願製) = 憲範襯艱選夢淵繭鹽鑰 遞襯壓鏇願鑰齋夢觸鏇 (鹽醖艱夢獵夢構憲憲鏇, 築餘獵蓋夢繭簾襯糧襯 ~ 餘鹽觸窪廠夢構積積鬱) 更多 | ||||||
N/A | - | Levofloxacin 500mg | 網衊襯獵選網壓齋鑰積(網窪鬱醖鬱夢鏇網積窪) = 範夢鏇餘築鏇製願願淵 餘壓糧鬱鹹蓋鹽膚淵獵 (窪齋獵衊窪憲鑰繭鹽積 ) | - | 2022-11-04 | ||
鏇廠遞構鹽齋鹽餘窪壓(遞艱構構遞淵築積廠餘) = 簾壓艱膚積積鹽齋願憲 醖網壓襯鹹膚築顧積鹽 (膚襯構構遞淵膚艱夢構 ) 更多 | |||||||
N/A | 10 | (higher than WHO dosage groups) | 獵築廠鬱鬱艱壓蓋鹽製(憲鹽築鑰願糧選遞餘製) = There was no adverse event of QT prolongation or any other grade 3 or 4 adverse events. 醖糧壓廠艱窪壓壓製壓 (積範簾餘膚窪積製蓋簾 ) | 积极 | 2022-07-13 | ||
(WHO dosage groups) |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
来和芽仔聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用